Financial Data and Key Metrics Changes - Net sales from continuing operations totaled $24.7 million, down from $28 million in Q1 2024, reflecting broader market softness [4] - Adjusted EBITDA from continuing operations improved significantly, swinging from a loss of $2.7 million in the prior year to a positive $843,000 this quarter, marking a $3.5 million turnaround [5][20] - Gross profit nearly doubled to $4.8 million, or 19.3% of sales, compared to $2.3 million, or 8.3% last year, an expansion of over 1,100 basis points [17] Business Line Data and Key Metrics Changes - Tubular Segments generated $6.9 million in revenue, down slightly year over year, but gross margin increased from 12.3% to 24.8%, with adjusted EBITDA rising nearly five times to $1.3 million [6] - Specialty Chemicals segment revenue declined year over year to $17.8 million, but gross profit increased by $2.1 million, rising from $1.6 million to $3.7 million, a 131% improvement, with gross margin expanding from 7.6% to 21% [9] Market Data and Key Metrics Changes - Average daily trading volume increased to approximately 63,000 shares in Q1 2025, a 60% lift compared to Q1 2024, indicating growing market interest [13] Company Strategy and Development Direction - The company is focused on strategic repositioning, actively choosing to exit low-margin business in favor of higher value, more technically demanding opportunities [15][16] - The goal for the Specialty Chemicals segment is to shift from a 75% commodity and 25% blended mix to a 60% and 40% mix by the end of 2025, aiming for a more balanced portfolio [35] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are signs of improvement, demand remains soft, and they are still evaluating options to monetize the value of their assets [28][29] - The company is not ready to provide forward-looking guidance for 2025, as they are still stabilizing their operations [30][31] Other Important Information - The company ended the quarter with $14.3 million in cash and no debt before the divestiture of Bristol assets for $45 million, providing significant flexibility for capital deployment [21][22] - The company repurchased approximately 17,000 shares at an average price of $12.73, reinforcing confidence in intrinsic value and long-term fundamentals [21] Q&A Session Summary Question: Comments on the ASTI business and its attractiveness as a target - Management indicated that while there are additional looks due to tariffs, demand remains incredibly soft, and the market conditions have not materially changed [28] Question: Possibility of selling ASTI in 2025 - Management confirmed they are always evaluating options to monetize the value of all assets [29] Question: Guidance for profitability in chemicals - Management stated it is premature to provide guidance as they are still stabilizing operations [30][31] Question: Growth plans for chemicals by 2026 - Management expects to see some growth in the second half of the year, with a more compelling top line anticipated in 2026 [33] Question: Capacity and CapEx for growth - Management confirmed that growth can be achieved with existing capacity and minimal CapEx, with a run rate of $1 to $3 million per year [36] Question: Stock buyback limitations - Management explained that the buyback was executed within the confines of the existing program, and optionality has increased post-Bristol sale [37] Question: Perception of stock valuation - Management expressed the opinion that the stock remains undervalued at current levels [38]